GRAIL, Inc. (GRAL) – What Are Brokerages Saying About This Stock?

Shares of GRAIL, Inc. (NASDAQ:GRAL) have received an average rating of “Hold” from the twelve research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $119.80.

Several research firms have recently issued reports on GRAL. Weiss Ratings restated a “sell (d-)” rating on shares of GRAIL in a report on Thursday, October 15th. Guggenheim upped their target price on GRAIL from $75.00 to $155.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Canaccord Genuity Group upped their target price on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 28th. Mizuho increased their target price on GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research report on Friday, September 25th. Finally, Morgan Stanley raised their price target on GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Monday, October 12th.

GRAIL Price Performance

NASDAQ:GRAL opened at $139.91 on Tuesday. The firm has a 50 day simple moving average of $104.22 and a 200-day simple moving average of $77.36. The firm has a market cap of $6.25 billion, a PE ratio of -14.35 and a beta of 2.83. GRAIL has a 1-year low of $41.50 and a 1-year high of $166.48.

GRAIL (NASDAQ:GRAL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share for the quarter, beating the consensus estimate of ($2.66) by $0.10. The company had revenue of $44.69 million during the quarter, compared to the consensus estimate of $42.39 million. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%. As a group, sell-side analysts expect that GRAIL will post -10.07 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Joshua Ofman sold 61,452 shares of the company’s stock in a transaction dated Monday, September 21st. The shares were sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the transaction, the chief executive officer owned 362,271 shares of the company’s stock, valued at $35,408,367.54. This represents a 14.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Partridge sold 7,873 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $1,152,528.47. Following the transaction, the insider owned 155,865 shares in the company, valued at approximately $22,817,077.35. The trade was a 4.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 129,944 shares of company stock valued at $14,832,805 in the last 90 days. 1.83% of the stock is currently owned by insiders.

Hedge Funds Weigh In On GRAIL

Institutional investors and hedge funds have recently bought and sold shares of the stock. Apollon Wealth Management LLC purchased a new position in GRAIL during the third quarter worth approximately $226,000. Slow Capital Inc. grew its stake in shares of GRAIL by 0.5% during the 3rd quarter. Slow Capital Inc. now owns 218,363 shares of the company’s stock valued at $30,597,000 after buying an additional 1,101 shares during the period. Root Financial Partners LLC purchased a new stake in shares of GRAIL during the 3rd quarter valued at $44,000. SBI Securities Co. Ltd. grew its stake in shares of GRAIL by 110.9% during the 3rd quarter. SBI Securities Co. Ltd. now owns 388 shares of the company’s stock valued at $54,000 after buying an additional 204 shares during the period. Finally, Pinnacle Associates Ltd. purchased a new stake in shares of GRAIL during the 3rd quarter valued at $208,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a healthcare company focused on developing blood-based screening technologies for the early detection of cancer. Its principal product is Galleri, a multi-cancer early detection test designed to identify DNA patterns associated with multiple types of cancer from a single blood sample.

Galleri is intended for use alongside recommended cancer screenings and is available by prescription through qualified healthcare providers in the United States. The test is offered as a laboratory-developed test and has not been approved or cleared by the U.S.